News | Stents Bioresorbable | March 11, 2016

Magnesium Elektron, Biotronik Partner to Develop Bioresorbable Alloy System

Ten-year research program led to development of SynerMag bioresorbable magnesium coronary scaffold

Biotronik, Magnesium Elektron, bioresorbable magnesium coronary scaffold, partner

Specially designed extrusion equipment at Magnesium Elektron’s purpose-built facility in England produces wire made from SynerMag bioresorbable magnesium alloy. Photo courtesy of Business Wire.

March 11, 2016 — Magnesium Elektron, developer, manufacturer and supplier of high-performance magnesium alloys, announced that Biotronik has been its partner in the development of its SynerMag bioresorbable magnesium alloys for cardiovascular application.

The two companies entered into a joint research and development program in 2006 aimed at developing a bioresorbable magnesium coronary scaffold. The ten-year research program has resulted in Elektron’s SynerMag 410 alloy system being used as the platform material in the Biotronik Magnesium Scaffold, what the company calls the world’s first clinically proven magnesium-based bioresorbable scaffold.

The latest generation Biotronik Magnesium Scaffold was clinically evaluated in the recent BIOSOLVE II study. The clinical data from BIOSOLVE II will be used to obtain CE approval for the device, and the release of the data was accompanied by publication in The Lancet.

Production of Elektron’s SynerMag 410 alloy system takes place in a new purpose-built manufacturing and testing facility in Manchester, United Kingdom. The facility, which achieved ISO 13485 approval in 2014, ensures Biotronik has a facility in its supply chain that will directly support its own production activities for the Biotronik Magnesium Scaffold.

For more information: www.biotronik.com, www.magnesium-elektron.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major